The Journal of Urology
Volume 177, Issue 2 , Pages 552-555 , February 2007

The Dual Serotonin and Noradrenaline Reuptake Inhibitor Duloxetine for the Treatment of Interstitial Cystitis: Results of an Observational Study

  • Arndt van Ophoven

      Affiliations

    • Corresponding Author InformationCorrespondence: Klinik und Poliklinik für Urologie, Universitätsklinikum Münster, Albert Schweitzer-Str. 33, 48129 Münster, Germany (telephone: ++-49-251-8347466; FAX: ++-49-251-8345279).
    • ,
  • Lothar Hertle

Received 6 April 2006

References 

  1. Nordling J. Interstitial cystitis: how should we diagnose it and treat it in 2004?. Curr Opin Urol. 2004;14:323
  2. van Ophoven A, Heinecke A, Hertle L. Safety and efficacy of concurrent application of oral pentosan polysulfate and subcutaneous low-dose heparin for patients with interstitial cystitis. Urology. 2005;66:707
  3. van Ophoven A, Hertle L. Long-term results of amitriptyline treatment for interstitial cystitis. J Urol. 2005;174:1837
  4. Szabadi E, Gaszner P, Bradshaw CM. The peripheral anticholinergic activity of tricyclic antidepressants: comparison of amitriptyline and desipramine in human volunteers. Br J Psychiatry. 1980;137:433
  5. Smith TR. Duloxetine in diabetic neuropathy. Expert Opin Pharmacother. 2006;7:215
  6. Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg L. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol. 1999;161:553–557
  7. O’Leary MP, Sant GR, Fowler FJ, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49:58
  8. Glantz SA. Primer of Biostatistics. 4th ed.. New York: McGraw-Hill; 1997;
  9. Rosamilia A, Clements JA, Dwyer PL, Kende M, Campbell DJ. Activation of the kallikrein kinin system in interstitial cystitis. J Urol. 1999;162:129
  10. Burkman RT. Chronic pelvic pain of bladder origin: epidemiology, pathogenesis and quality of life. J Reprod Med. 2004;49:225
  11. Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther. 2005;312:726
  12. Restorick JM, Mundy AR. The density of cholinergic and alpha and beta adrenergic receptors in the normal and hyper-reflexic human detrusor. Br J Urol. 1989;63:32
  13. Gillespie JI. Noradrenaline inhibits autonomous activity in the isolated guinea pig bladder. BJU Int. 2004;93:401
  14. Birder LA, Apodaca G, DeGroat WC, Kanai AJ. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol. 1998;275:F226
  15. de Groat WC. Influence of central serotonergic mechanisms on lower urinary tract function. Urology. 2002;59:30
  16. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther. 1995;274:1014
  17. Oelke M, Roovers JP, Michel MC. Safety and tolerability of duloxetine in women with stress urinary incontinence. BJOG. 2006;113:22
  18. Prescribing information for physicians. Available at http://www.fda.gov/cder/foi/label/2004/21733lbl.pdf. Page 19, line 679. Accessed April 4, 2006.

PII: S0022-5347(06)02486-4

doi: 10.1016/j.juro.2006.09.055

The Journal of Urology
Volume 177, Issue 2 , Pages 552-555 , February 2007

Article Tools